China's medical products administrator approved Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Pharma (Xuzhou)'s drug registration for venlafaxine hydrochloride sustained-release tablets.
The drug is indicated for depression, including depression with anxiety, and general anxiety disorder, according to a Thursday filing with the Hong Kong Exchange.
Shares rose 1% in Hong Kong during Friday's trading.
Price (HKD): $13.98, Change: $+0.16, Percent Change: +1.16%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。